Background: Vinorelbine, is an active drug in the treatment of metastatic breast cancer and has a favorable toxicity profile. Its combination with other effective and well-tolerated cytotoxics may thus be beneficial. We investigated the therapeutic effect of a combination of vinorelbine plus 5-fluorouracil and folinic acid as first-line treatment in patients with metastatic breast cancer.
Introduction
Polychemotherapy regimens containing anthracyclines or taxanes, often used as first-or second-line systemic treatments for patients with advanced breast cancer, yield response rates of 50% to 70% with a median duration of 8-16 months. Patients selected to be treated with these regimens are reported to have a median overall survival of less than two years [1] .
In most patients disease progression, after first-line chemotherapy, typically requires a second-line chemotherapy. Anthracyclines are often given to achieve palliation, but their increased employment in the adjuvant setting represents a hindrance, thus demand the testing of new effective regimens with a favorable therapeutic index. Patients who relapse or have progressive disease during or immediately after anthracycline treatment have a poor prognosis, and a less than 15% chance of achieving an objective response when treated with cytotoxic agents such as cisplatin, mitomycin-C or mitoxantrone [1] . Higher response rates of 20% to 30% have been reported with taxanes [2] , the use of which is, however, associated with some unpleasent cumulative side effects, especially in responders who require longer treatment duration. The developement of effective and well tolerated second-line regimens in this setting is therefore a genuine clinical challenge.
Vinorelbine is a semisynthetic vinca alkaloid that has cytocidal effect on a wide range of tumor cell lines [3] [4] [5] [6] . It is a mitotic inhibitor that has a higher therapeutic index and less neurotoxicity than other vinca alkaloids related to the lower degree of damage of axonal microtubules [7] . The dose limiting toxicity of vinorelbine is granulocytopenia [8] .
Given as single agent the drug yields response rates of 40% to 60% in previously untreated patients [9] [10] [11] [12] [13] , and of about 30% when used as a second-or third-line therapy [14] [15] [16] [17] .
A randomized study comparing vinorelbine with melphalan in patients with anthracycline-refractory metastatic breast cancer demonstrated the superiority of vinorelbine in terms of response rates, time to disease progression and median survival [18] .
The impressive effectiveness observed with vinorelbine as single agent and its favorable toxicity profile led to its testing in combination with other cytotoxics in metastatic breast cancer setting. Such regimens included doxorubicin, with response rates similar to some most effective standard combinations [19] , mitoxantrone [20, 21] and 5-fluorouracil [22] .
We therefore started a phase I study in metastatic breast cancer using vinorelbine together with 5-fluorouracil and folinic acid, a combination based upon the efficacy of both drugs in breast cancer, the low burden of subjective side-effects associated with their use, and their different toxicity profiles, 5-fluorouracil being moderately myelotoxic.
The aims of this study were: a) to evaluate the feasibility of such regimen and b) to establish the Maximum Tolerated Dose (MTD) of vinorelbine when administered in a three-day schedule with 5-fluorouracil and high-dose folinic acid.
Since we obtained good results in the first six patients [three at first dose level of vinorelbine (25 mg/m
2 )] and three at second dose level (30 mg/m 2 ), we started a phase II study in order to evaluate the activity of this regimen as first-line treatment for patients with metastatic breast cancer. We decided to administer high doses of folinic acid in an attempt to maximize the effect of the three-day schedule of low-dose 5-fluorouracil [23, 24] .
The combined data from these two investigations are the subject of this report.
Patients and methods

Eligibility criteria
Patients with histologically proven, measurable or evaluable progressive metastatic breast cancer, who had not received chemotherapy for metastatic disease, were eligible for this study. The other eligibility criteria were an age of more than 18 years; an ECOG performance status of 0-2; an expected survival >3 months; reasonable bone marrow function (absolute granulocyte count >4000/mm 3 , platelet count > 100.000 /mm 3 , and hemoglobin level >11 g/dl); adequate hepatic and renal function, including AST, ALT, bilirubin, alkaline phosphatase and serum creatinine values < 1.25 times the upper limit of normal; no severe uncontrolled co-morbidities and no second malignancies. Informed consent was obtained before entry.
Clinical monitoring was performed once weekly with a complete blood count.
Toxicity was evaluated according to NCIC-CTG criteria by clinical and laboratory evaluations at day 21 of each cycle.
Antitumor activity was evaluated every two courses (i.e., six weeks) on all measurable lesions and all of the patients were scheduled for at least two cycles in order to be eligible for assessment of tumor response. In patients with tumor responses or stable disease, the treatment was continued to a maximum of eight cycles.
Tumor response was classified according to WHO criteria and documented by two investigations at least six week apart.
Complete response (CR) was defined as the disappearance of all clinical evidence of active tumor, with complete reossification of bone lesions and the absence of any disease-related symptoms for a minimum four weeks. Partial response (PR) was defined as a > 50% reduction in the sum of the products of the perpendicular diameters of all measurable lesions, without the appearance of any new lesions for at least four weeks. In the case of multiple metastatic sites of disease, the largest masses (up to five) were considered as the index lesions.
Minor response (MR) was defined as a decrease in tumor size of less than 50% but more than 25%, for at least four weeks. Stable disease (SD) was defined as a less than 25% decrease or a less than 25% increase in tumor size for at least four weeks. Progressive disease (PD) was denned as the unequivocal appearance of any new lesion or an increase of > 25% in the sum of the perpendicular diameters of any measured lesion or in the estimated size of an unmeasurable lesion. MR, SD, and PD were considered to be treatment failures.
The Kaplan-Meier method was used to analyse the time to progression (1 IF) and overall survival (OS) [25] . The confidence intervals for the response rates were calculated by means using the method described by Simon [26] . The sequential two-step statistical test of Gehan was used to define the number of patients required to detect activity of the treatment [30] .
Treatment plan
Phase I
The treatment consisted of a fixed dose of 100 mg/m 2 folinic acid (levo isomer) administered by injection into a running intravenous (i.v.) infusion of dextrose 5% or normal saline over a period of 10 minutes on day 1, 2 and 3, followed by a 5-fluorouracil fixed dose of 350 mg/m 2 administered by means of an i.v. infusion of 15 minutes on day 1, 2, and 3. Vinorelbine was started at 25 mg/m 2 diluted with 75-125 ml of normal saline or dextrose 5%, and infused for 20 minutes on day 1 and 3. Dexametasone, 8 mg i.v. on day one and three and 4 mg i.v. on day 2, was used as prophylactic antiemetic treatment. Treatment was administered on an outpatient basis every three weeks.
A vinorelbine dose escalation (5 mg/m 2 per level including three or six patients each) was projected if no dose limiting toxicity occurred in one out of three or two out of six patients per dose level, respectively. Dose-limiting toxicities were defined as NCIC-CTG grade 3 granulocytopenia associated with grade >2 infection, and/or grade >2 constipation, mucositis, stomatitis or diarrhea.
Granulocytopenia without infection was not considered dose-limiting toxicity; the prophylactic use of granulocyte colony stimulating factors was not considered.
If a patient experienced any of dose-limiting toxic effect, the vinorelbine dose was reduced by 20% for the rest of treatment period.
Pretreatment evaluation and follow-up studies
The pretreatment evaluation included medical history and physical examination with tumor measurements: chest X-ray, complete blood cell count, serum chemistries, liver function tests and tumour marker determination; staging studies appropriate to define the extent of metastatic disease which included abdominal ultrasound, thoracic and/or abdominal CT, bone scan, as indicated by clinical or laboratory examination.
Results
Patient characteristics
From May 1994 and June 1996, 45 patients with advanced breast cancer entered this phase I-II study: six patients in the phase I study (three patients at dose level 1 and three at dose level 2) and 39 in the subsequent phase II study. All of the evaluable patients had at least one measurable tumor site. Three patients were ineligible: one refused the treatment after the first cycle (phase I) and two had only unmeasurable bone disease (phase II). The characteristics of the patients treated in the phase II study are shown in Table 1 (n -39). Their median age was 51 years (range, 35 to 71); ECOG performance status was 0-1 in 34 patients and 2 in five. Twenty-five patients were postmenopausal, and 19 estrogen receptor positive. None of the patients had received prior chemotherapy for advanced disease, although 21 of the 39 patients in the phase II study had received prior chemotherapy in adjuvant setting, 13 of them (33%) with an anthracycline-containing regimens. Thirteen patients had received prior adjuvant hormonotherapy with tamoxifen. None of the patients had received prior radiotherapy for advanced disease. The median time elapsed from primary diagnosis to study entry was 13 months (range 0 to 113); none of the patients had experienced failure of adjuvant anthracycline treatment within six months of therapy completion (median time since anthracyclines 17, range 8 to 76).
The site of metastatic disease were bone (36%), lymphnodes (41%), lung (41%), liver (38%) and soft tissue (24%). The number of organ sites by patients were 1 in 18, 2 in 13 and more than 2 in 8 patients.
Toxicity
Phase I Dose level 1. No dose-limiting toxicities were observed in the first three patients treated at dose level 1 (19 cycles). Two patients developed grade 3 granulocytopenia at least once, and one grade 4, with nadir on day 9 and complete recovery within day 16, without fever. Nonhematologic toxicity was minimal: grade 1 peripheral neuropathy in all three patients and grade 1 constipation in one case.
Dose level 2.
In this group of patients, vinorelbine was administered at a dose of 30 mg/m 2 . Hematologic toxicity showed no differences in terms of the median nadir, the days of nadir and the day of recovery; two patients developed grade 4 granulocytopenia at least once, with nadir on day 9 and complete recovery within day 16, without fever. Grade 1 thrombocytopenia was observed in one patient.
All patients treated at this dose level developed grade 4 peripheral neuropathy; grade 4 of 'ileus-like syndrome' with fever (grade 2) requiring hospitalization and supportive care was observed in two out of them.
Peripheral neuropathy occurred as an extrapyramidal-like reaction with sharp posterior neck pain irradiating to the nucal area, neck stiffness and difficulties in chewing; the symptoms began within six days of starting the cycle, lasted 48 to 72 hours and were followed by constipation in all cases. The only medication that was able to reverse this symptomatology was biperiden. The higher incidence and extent of these symptoms might be related to the short interval between the two administration of vinorelbine which resulted in a high peak blood concentration of vinorelbine.
After the enrollment of the first six patients, we concluded that the maximum tolerated dose of vinorelbine is 25 mg/m 2 when administered on a three-day schedule, in combination with 5-fluorouracil and folinic acid.
Phase II
All of the evaluable patients received at least one cycle of therapy; the median number of cycles administered was six (range: one to eight cycles).
Of the 229 cycles administered during the phase II study, eight were delayed, six because of hematologic toxicity, and the remaining two for non-medical reason. Five patients required a dose reduction of vinorelbine in 13 cycles (by 25% in eight and by 50% in five cycles); four cycles of 5-fluorouracil were administered at 75% of total dose in one patient.
Mean (Table 2) . Recovery was fast and universal. Grade 3 and 4 nadirs generally lasted no more than seven days. Sixteen epi- Table 2 Summary of hematologic toxicity (n = 39). The non-hematological toxicities are listed in Table 3 . Mild peripheral neuropathy, limited to paresthesias and insomnia, occurred in 15 patients, (grade 1 in 11 patients, grade 2 in three and grade 3 in one). In no case neurotoxicity was dose-limiting and it was always reversible. Of the 29 patients who received six cycles or more none had residual peripheral neuropathy-related symptoms.
Constipation was reported in 25 patients (15 at grade 1, six at grade 2 and four at grade 3).
A low incidence of alopecia was observed, affecting 40% of patients with only 4 classified as grade 2. Other side effects included nausea or vomiting, mucositis and diarrhea, were generally mild. In three patients with peripheral phlebitis requiring treatment, a central venous access was implanted. No significant alterations were observed in blood chemistry tests.
Response to therapy
Phase I Dose level 1. One of the three patients treated at first dose level achieved a complete response and two had stable disease after two cycles of therapy.
Dose level 2.
Two of the three patients treated at this dose level achieved a partial response; one patient refused the treatement after the first cycle and was not evaluated for response.
In the first six patients we observed one complete response, two partial responses and two cases of stable disease.
This observation at this first dose level motivated the phase II study.
Phase II
The response data are listed in Table 4 . The median duration of follow-up in the 39 evaluable patients was 15 months (range 4 to 31). The objective response rate (CR plus PR) was 62% (95% CI, 47% to 77%), including seven patients (18%) with CR and 17 (44%) with PR. Nine patients experienced SD and six progressed on treatment. The overall response rates by site were assessed on measurable disease, and are displayed in Table  5 . Responses were observed over the entire range of metastatic sites, the overall response rate being 62% for lung metastases, 60% for liver, 63% for lymph-nodes, 89% for skin, 88% for local relapses and 36% for bone disease. The median response duration was 10 months (range 6 to 24+). The median time to progression was eight months (range 2 to 24+). The median survival time has not been reached; the 12-month survival rate is 78%.
Discussion
For women with advanced breast cancer, chemotherapy is, at best, a palliative measure, offering limited expectation of prolonged survival. The main goal of any treatment chosen for metastatic disease is therefore to obtain complete symptomatic relief, ideally through tumor regression. The efficacy of available regimens yielding response rates ranging from 40% to 90%, and median response durations of 5-12 months, is well established, while their positive effect on overall survival is controversial.
Intensive treatments, such as doxorubicin, taxoids, and platinum-containing regimens have shown significant increase of response rates and duration, obtained however at the cost of major toxic effects. Tiredness, nausea, lack of appetite, and especially, alopecia are of a significant subjective burden, and represent important issues when discussing treatment options with patients. (29) 8 (88) 3 (19) 1 (7) 3 (19) 2 (22) 1 (7) 0 3 (19) 4 (27) 4 (25) 1 (11) 7 (43) 1 (12) 3 (19) 2 (13) Although women with metastatic breast cancer are offered more extensive therapeutic choices than patients with most advanced malignancies, regimens with high response rates and minimal toxicity are obviously warranted.
Anthracycline-based therapy is considered the most significant treatment for palliation due to its anti-tumor effects and despite its subjective and objective toxicities. However, the higher number of patients who receive anthracycline-containing regimens in adjuvant or neoadjuvant programs, has increased the need for an effective and well tolerable regimen for the treatment of patients relapsing after anthracycline exposure.
The response rates obtained with vinorelbine administered as single agent are similar to those of other drugs (e.g., cyclophosphamide, methotrexate, doxorubicin, mitoxantrone, 5-fluorouracil and mitomycin-Q, all considered effective as single agents in advanced breast carcinoma, and typically used in chemotherapy regimens for both advanced or operable disease [1] .
Combination chemotherapy regimens are generally thought to be more effective than single-agent chemotherapy in advanced breast cancer [28] [29] [30] [31] . The high remission rates observed with vinorelbine as a single agent as well as its low toxicity profile, makes it a very attractive proposition for combination with other active compounds.
The combination of vinorelbine, 5-fluorouracil and folinic acid, tested in this study was selected in an attempt to obtain a regimen with a particularly favorable outline of subjective toxicity. The choice to administer vinorelbine on days 1 and 3 was made based upon its plasma concentration profile which decrease in a triexponential manner, with a terminal phase half-life of about forty hours [32, 33] . Furthermore, most patients do not tolerate a weekly dose of 30 mg/m 2 (the recommended dose for phase II studies), neutropenia being the limiting toxicity, typically requiring dose reductions and delays in administration. Vinorelbine can be easily combined with 5-fluorouracil, a very active compound against breast cancer [1, [22] [23] [24] which is only moderately myelosuppressive.
In this study the combination of, 5-fluorouracil, folinic acid and vinorelbine (FLN regimen), showed considerable efficacy, with an overall response rate of 62% and a complete remission (CR) rate of 18% (95% CI, 47% to 77%). The responses achieved were longlasting, with a median response duration of 10 months. The median survival of the patient population has not yet been reached; the 12-month survival is 78%.
It is interesting to note that the overall response rate was not related to the patterns of metastatic presentation: responses were observed in 61% of visceral and 64% of non-visceral sites. Prior exposure to adjuvant chemotherapy with anthracycline-containing regimens (in the adjuvant setting) did not seem to influence response: the remission rates were 58% in untreated patients, and 54% in those who had been previously treated; however, the number of these patients, is too small and none of them experienced failure of adjuvant anthracycline treatment within six months of therapy completion (median 17, range 8 to 76).
The limiting toxicity of this combination, in which vinorelbine was given on a three-day schedule, was hematological: grade 3-4 neutropenia, recorded at nadir, was experienced by almost all patients at least on one occasion. Neutropenia, however, did not seem to be cumulative and its duration was typically no longer than seven days. Only eight courses required delayed administration, vinorelbine was administered at 98% of the overall scheduled doses, and fluorouracil at 99%. The neurological toxicity of vinorelbine was closely monitored, but only one patient experienced grade 3 peripheral neuropathy with predominant numbness and parasthesiae. Autonomic neuropathy causing grade 4 constipation was observed in only two patients who were treated at the second dose level of vinorelbine (i.e., 30 mg/m 2 ). The neurotoxicity was reversible in all cases. No other significant toxic events were observed in other organs, although four patients experienced grade 2 alopecia.
In conclusion, the FLN combination of vinorelbine, 5-fluorouracil and folinic acid proved to be an effective first line treatment for metastatic breast cancer. Its advantages over other commonly used cytotoxic combinations is its excellent subjective tolerability. Patients especially appreciate the very low incidence of nausea and vomiting or alopecia. Moreover, 44% of the patients complaining cancer-related symptoms at entry, showed a reduction in their intensity during the course of the first treatment.
The fact that this effective regimen was subjectively well tolerated offers the opportunity for a number of future developments, including further investigations on the best way of combining these drugs, and its use as an adjuvant and neoadjuvant treatment.
